Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Issue 6 (14th February 2023)
- Record Type:
- Journal Article
- Title:
- Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Issue 6 (14th February 2023)
- Main Title:
- Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma
- Authors:
- Handa, Takafumi
Hayashi, Takuo
Ura, Ayako
Watanabe, Isamu
Takamochi, Kazuya
Onagi, Hiroko
Kishi, Monami
Matsumoto, Naohisa
Tajima, Ken
Kishikawa, Satsuki
Saito, Tsuyoshi
Takahashi, Kazuhisa
Suzuki, Kenji
Yao, Takashi - Abstract:
- Aims: Subtypes of small cell lung carcinoma (SCLC) are defined by the expression of ASCL1, NEUROD1, and POU2F3 markers. The aim of our study was to explore the extent to which the intratumoral heterogeneity of ASCL1, NEUROD1, and POU2F3 may lead to discrepancies in expression of these markers in surgical samples and their matched tissue microarray (TMA) and lymph node (LN) metastatic sites. Methods and results: The cohort included 77 patients with SCLC. Immunohistochemical examinations were performed on whole slides of the primary tumour, paired TMAs, and metastatic LN sites. Samples with H‐scores >50 were considered positive. Based on the ASCL1, NEUROD1, and POU2F3 staining pattern, we grouped the tumours as follows: ASCL1‐dominant (SCLC‐A), NEUROD1‐dominant (SCLC‐N), ASCL1/NEUROD1 double‐negative with POU2F3 expression (SCLC‐P), and negative for all three markers (SCLC‐I). In whole slides, 40 SCLC‐A (52%), 20 SCLC‐N (26%), 15 SCLC‐P (20%), and two SCLC‐I (3%) tumours were identified. Comparisons of TMAs or LN metastatic sites and corresponding surgical specimens showed that positivity for ASCL1, NEUROD1, and POU2F3 in TMAs (all P < 0.0001) or LN metastatic sites (ASCL1, P = 0.0047; NEUROD1, P = 0.0069; POU2F3, P < 0.0001) correlated significantly with that of corresponding surgical specimens. Conclusion: The positivity for these markers in TMAs and LN metastatic sites was significantly correlated with that of corresponding surgical specimens, indicating that biopsyAims: Subtypes of small cell lung carcinoma (SCLC) are defined by the expression of ASCL1, NEUROD1, and POU2F3 markers. The aim of our study was to explore the extent to which the intratumoral heterogeneity of ASCL1, NEUROD1, and POU2F3 may lead to discrepancies in expression of these markers in surgical samples and their matched tissue microarray (TMA) and lymph node (LN) metastatic sites. Methods and results: The cohort included 77 patients with SCLC. Immunohistochemical examinations were performed on whole slides of the primary tumour, paired TMAs, and metastatic LN sites. Samples with H‐scores >50 were considered positive. Based on the ASCL1, NEUROD1, and POU2F3 staining pattern, we grouped the tumours as follows: ASCL1‐dominant (SCLC‐A), NEUROD1‐dominant (SCLC‐N), ASCL1/NEUROD1 double‐negative with POU2F3 expression (SCLC‐P), and negative for all three markers (SCLC‐I). In whole slides, 40 SCLC‐A (52%), 20 SCLC‐N (26%), 15 SCLC‐P (20%), and two SCLC‐I (3%) tumours were identified. Comparisons of TMAs or LN metastatic sites and corresponding surgical specimens showed that positivity for ASCL1, NEUROD1, and POU2F3 in TMAs (all P < 0.0001) or LN metastatic sites (ASCL1, P = 0.0047; NEUROD1, P = 0.0069; POU2F3, P < 0.0001) correlated significantly with that of corresponding surgical specimens. Conclusion: The positivity for these markers in TMAs and LN metastatic sites was significantly correlated with that of corresponding surgical specimens, indicating that biopsy specimens could be used to identify molecular subtypes of SCLC in patients. Abstract : … (more)
- Is Part Of:
- Histopathology. Volume 82:Issue 6(2023)
- Journal:
- Histopathology
- Issue:
- Volume 82:Issue 6(2023)
- Issue Display:
- Volume 82, Issue 6 (2023)
- Year:
- 2023
- Volume:
- 82
- Issue:
- 6
- Issue Sort Value:
- 2023-0082-0006-0000
- Page Start:
- 860
- Page End:
- 869
- Publication Date:
- 2023-02-14
- Subjects:
- ASCL1 -- NEUROD1 -- POU2F3 -- small cell carcinoma
Histology, Pathological -- Periodicals
611.018 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=his ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2559 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/his.14872 ↗
- Languages:
- English
- ISSNs:
- 0309-0167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4316.027000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26920.xml